News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Merck KGaA’s Erbitux Gets Green Light for Head Cancer
October 24, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
FRANKFURT, Oct 24 (Reuters) - A committee of experts advising the European Commission said on Friday it backed Merck KGaA's Erbitux drug for a second use to combat head and neck cancer, bolstering its sales potential in the region.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Complete response letters
Capricor Plunges on FDA Rejection of DMD Cell Therapy
July 11, 2025
·
3 min read
·
Tristan Manalac
FDA
FDA Rejections: We Read 200 CRLs So You Don’t Have To
July 11, 2025
·
5 min read
·
Annalee Armstrong
Complete response letters
FDA Publishes Cache of Complete Response Letters in Bid for ‘Radical Transparency’
July 10, 2025
·
2 min read
·
Dan Samorodnitsky
Government
Kennedy Postpones Preventive Care Panel Meeting After ‘Double-Edged Sword’ Supreme Court Win
July 10, 2025
·
2 min read
·
Tristan Manalac
